✦ LIBER ✦

Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate

✍ Scribed by G. LeMarbre; C. Schinstock; R. Hoyer; J. Krook; A. Tefferi

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 61 KB
Volume: 31
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2006.08.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chronic myeloid leukemia wi

Treatment of chronic myeloid leukemia with imatinib mesylate

✍ Ryuzo Ohno 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 271 KB

Update on practical aspects of the treat

Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate

✍ Jeffrey A. Zonder; Charles A. Schiffer 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 292 KB

Successful treatment of chronic myeloid

Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis

✍ Evren Ozdemir; Yener Koc; Emin Kansu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Acute myeloid leukemia developing during

Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities

✍ Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Ba 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 171 KB

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been

Imatinib mesylate induces hypophosphatem

Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response

✍ S. Osorio; A. García Noblejas; A. Durán; J.L. Steegmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

Erythropoietin is effective in improving

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

✍ Jorge Cortes; Susan O'Brien; Alfonso Quintas; Francis Giles; Jianquin Shan; Mary 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract ## BACKGROUND Myelosuppression occurs in up to 50% of patients with chronic myeloid leukemia (CML) who are treated with imatinib and ≥ Grade 3 myelosuppression is reported in approximately 10% of patients. ## METHODS The authors investigated the prognostic significance of anemia occu